4 or less days of fever, shortened by early treatment, were equivalent to patients who experienced 5 or more febrile days in the previous criteria. Our hypothesis was that the revision of the diagnostic guideline would increase the proportion of patients who were treated with IVIG within 4 days of illness onset and result in lower cardiovascular sequelae. The objective of this study was to investigate our hypothesis, using the database of the nationwide surveys.
Methods
Nationwide surveys of KD have been conducted in Japan every 2 years since 1970 and have been described previously. 5, 6, 10, 11 In the present study, the new criteria group comprised patients who received the diagnosis of KD during the period of January 1, 2003 through December 31, 2004 in the 18 th nationwide survey (n=19,138). The old criteria group was comprised patients who received their diagnosis during the period of January 1, 1999 through December 31, 2000 in the 16 th nationwide survey (n=15,314). Duplicate reported patients (n=646) were excluded, leaving a total of 33,806 patients for the analysis.
The following data were obtained: age, sex, recurrence, diagnostic categories, first day of hospital visit, IVIG treatment, additional IVIG treatment, and cardiovascular disorders. Laboratory data were not obtained in the nationwide surveys.
The cardiovascular disorders were divided into 2 categories according to the duration of their condition: transient dilation and cardiovascular sequelae. Transient dilation was defined as coronary artery dilation or aneurysm in an acute stage with no lesions 1 month after the onset of the disease. Background The aim of this study was to investigate the effect of a revision of the fever criterion for initial intravenous immunoglobulin (IVIG) treatment, and cardiovascular sequelae, in the new Japanese diagnostic criteria for Kawasaki disease.
Methods and Results
Patients who were reported in the 16 th and 18 th nationwide surveys in Japan were analyzed. New criteria group comprised patients who received the diagnosis of Kawasaki disease in the 18 th nationwide survey (n=18,789). Old criteria group was comprised patients who received their diagnosis in the 16 th nationwide survey (n=15,017). The difference between the new and old criteria for complete cases was only 1%. The proportion of patients who were treated with IVIG within 4 days of illness onset in the new criteria group was significantly lower than in the old criteria group (27.7% vs 30.7%). Multivariate logistic regression analysis identified criteria sex, age, recurrence, diagnosis, last day of initial IVIG and additional IVIG treatment as significant independent factors for cardiovascular sequelae. 
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Cardiovascular sequelae were defined as at least 1 of the following symptoms existing at 1 month after the onset of the disease: CAA, coronary stenosis, myocardial infarction, or valvular lesion. The criteria for defining a CAA or other abnormality are set out by the Japanese Ministry of Health. 12 
Statistical Analysis
Nominal data were analyzed with a chi-square test. Continuous variables were compared with the Student's t-test. Logistic regression analysis was performed to select factors significantly associated with cardiovascular sequelae. The model was simplified in a stepwise fashion by removing variables which had a p value of greater than 0.05. A p-value <0.05 was considered statistically significant. Analyses were performed using SPSS 11.0 (SPSS Inc, Chicago, IL, USA).
Results
Patients Characteristics (Table 1) The proportion of males was similar in the 2 groups. The proportion of patients younger than 1 year old in the new criteria group was significantly lower in comparison with the old criteria group. The proportions of complete cases and recurrence (a second or more episode of the disease separate from the first) were significantly higher in the new criteria group. First day of hospital visit in the new criteria group was significantly earlier than for the old criteria group.
The proportion of patients treated with IVIG was similar between the 2 groups. The proportion of patients who were treated with IVIG within 4 days of illness onset in the new criteria group was significantly less than in the old criteria group. The last day of initial IVIG treatment in the new criteria group was significantly earlier than for the old criteria group. The daily and total dose of initial IVIG treatment in the new criteria group was significantly higher than in the old criteria group. The proportion of patients who required more than 1 IVIG treatment was significantly higher in the new criteria group.
Cardiovascular Disorders (Table 2)
The proportion of patients who received IVIG treatment and were complicated with cardiovascular disorders was significantly lower in the new criteria group (13.9% vs 19.0%, p<0.001). However, the proportion of patients who did not receive IVIG treatment and had complicated cardiovascular disorders was similar in both groups (10.5% vs 11.3%, p=0.4). In total, the percentages of patients with transient dilation and cardiovascular sequelae were significantly lower in the new criteria group in comparison with the old criteria group.
Patients Treated With IVIG Within 4 Days of Illness Onset
The proportion of patients who were treated with highdose (>700 mg/kg per day) IVIG within 4 days of illness onset was significantly lower than those treated after 5 days of illness (68.1% vs 69.8%, p=0.004). The proportion of transient dilation in patients treated with IVIG within 4 days of illness onset was similar to that for the patients treated after 5 days of illness (11.8% vs 11.3%, p=0.2). However, the proportion of cardiovascular sequelae in patients treated with IVIG within 4 days of illness onset was significantly higher than in those treated after 5 days of illness (5.9% vs 4.9%, p=0.001). (Table 3) Multivariate logistic regression analysis identified criteria sex, age, recurrence, diagnosis, last day of initial IVIG and additional IVIG treatment as significant independent factors for cardiovascular sequelae. Treatment with IVIG within 4 days of illness onset (p=0.06) and daily dose of initial IVIG (p=0.3) were not significant factors for cardiovascular sequelae.
Factors Associated With Cardiovascular Sequelae

Discussion
Contrary to our hypothesis, the proportion of patients who were treated with IVIG within 4 days of illness onset in the new criteria group did not increase, compared with the old criteria group, despite an earlier hospital visit. This result would explain why approximately 30% of patients in the old criteria group were treated within 4 days of illness. In addition, health insurance approval in July 2003 of a single 2,000 mg/kg IVIG treatment would make it easy to complete the initial treatment within 9 days of illness onset. In fact, the percentage of patients initially treated with IVIG and completed within 9 days of illness onset in the new criteria group was higher than in the old criteria group. Together with the result that the odds ratio of the last day of IVIG treatment for cardiovascular sequelae was higher than that of the initial day of IVIG, early completion of IVIG therapy was more important than an early start of treatment.
In the present study, only a 1% increase of complete cases was observed in the new criteria group compared with the old criteria group. In addition, patients who had 4 days and less of fever in the new criteria group comprised only 3.7%; most of these patients did not fulfill the old criteria. According to these results, the criteria revision improved diagnostic sensitivity by only a few percentage points.
However, we again demonstrated in the present study that having the initial day of IVIG treatment within the first 4 days of illness was not a significant risk factor for cardiovascular sequelae compared with those who began therapy after 5 days of illness. 10 This result justifies both beginning IVIG treatment within 4 days of illness onset and the revision of the fever criterion. In addition, early treatment could result in more patients completing initial IVIG treatment within 9 days of illness onset.
We also demonstrated that the old criteria group had a significant risk factor for cardiovascular sequelae. However, another factor associated with the decrease of cardiovascular sequelae might be bias, one of which would be improvement of additional rescue therapy such as the use of steroids, ulinastatin, and plasmapheresis. Unfortunately, we did not collect information about these adjunctive therapies in the 16 th survey and could not compare the difference. However, the proportion of patients in the new criteria group who received additional IVIG treatment was significantly higher than in the old criteria group. Therefore, the higher proportions of use of additional steroid, ulinastatin, and plasmapheresis in the new criteria group could be expected. This study is also limited because we did not collect data concerning other clinical features, the date of diagnosis, or laboratory data. We also did not control the treatment regimens, so the diagnostic methods of cardiovascular disorders might be biased. 13 In summary, the guideline revision improves diagnostic sensitivity slightly, but reflects the clinical reality of the disease that approximately 30% of patients are treated with IVIG within 4 days of illness onset.
